CHU Clermont-Ferrand

Dec 5, 2024 | ejso.com | CHU Clermont-Ferrand |Hôpital Saint-Antoine |Biostatistic Unit

Keywordsgastric adenocarcinomaoverweightobesitymorbiditysurgeryGet full text accessLog in, subscribe or purchase for full access. References1. Boutari, C. ∙ Mantzoros, C.S.A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage onMetabolism. 2022; 133, 1552172. Pata, G. ∙ Solaini, L. ∙ Roncali, S. ...

Jul 5, 2024 | bmccancer.biomedcentral.com | CHU Clermont-Ferrand

Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial) Correction Open access Published: 05 July 2024 BMC Cancer volume 24, Article number: 806 (2024) Cite this article The Original Article was published on 30 May 2024 Correction: BMC Cancer 24, 661 (2024) Following publication of the original article [1], it...

Jun 7, 2024 | academic.oup.com | CHU Clermont-Ferrand

Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.

May 30, 2024 | bmccancer.biomedcentral.com | CHU Clermont-Ferrand

Methods and analysisThe BIO-TIMER study is a multi-center, prospective, longitudinal study aiming to evaluate the value of combining BA determination with individual frailty assessment to personalize the management of CML patients treated with TKI. This study has been registered on Clinicaltrials.gov (NCT06130787). A maximum of 321 patients are expected to be enrolled. The study was started in November 2023 with a 2-year enrolment period and an estimated completion date by November 2028.

Apr 24, 2024 | academic.oup.com | CHU Clermont-Ferrand |Clermont Auvergne

Despite the use of validated guidelines in the management of mild traumatic brain injury (mTBI), processes to limit unnecessary brain scans are still not sufficient and need to be improved. The use of blood biomarkers represents a relevant adjunct to identify patients at risk for intracranial injury requiring computed tomography (CT) scan. Biomarkers currently recommended in the management of mTBI in adults and children are discussed in this review.